Vascular dysfunction and increased metastasis of B16F10 melanomas in Shb deficient mice as compared with their wild type counterparts

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Zang, Guangxiang ^a,c   Gustafsson, Karin ^a   Jamalpour, Maria ^a   Hong, Jong Wook ^b   Genové, Guillem ^b   Welsh, Michael ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

CD8+ cells; Melanoma; Metastasis; Pericytes; Shb; Vascular permeability

Indexed keywords

ADAPTOR PROTEIN; CD31 ANTIGEN; CD8 ANTIGEN; DESMIN; PROTEIN SHB; RNA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; ONCOPROTEIN; SHB PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION PROFILING; HEMATOPOIESIS; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOLOGY; LUNG METASTASIS; MELANOMA; MELANOMA B16F10; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PERICYTE; PROTEIN DEFICIENCY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STRAIN DIFFERENCE; VASCULAR DISEASE; WILD TYPE MOUSE; ANIMAL; CAPILLARY PERMEABILITY; DEFICIENCY; DISEASE MODEL; EXPERIMENTAL MELANOMA; GENE EXPRESSION; GENETICS; GENOTYPE; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SECONDARY; TUMOR VOLUME;

ANIMALS; BONE MARROW TRANSPLANTATION; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENOTYPE; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROTO-ONCOGENE PROTEINS; TUMOR BURDEN;

EID: 84926619203     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1269-y     Document Type: Article

References (49)

1. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339(6219):58-61.
2. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
3. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
4. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232-9.
5. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220-31.
6. Anneren C, Lindholm CK, Kriz V, Welsh M. The FRK/RAK-SHB signaling cascade: a versatile signal-transduction pathway that regulates cell survival, differentiation and proliferation. Curr Mol Med. 2003;3(4):313-24.
7. Holmqvist K, Cross MJ, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T, et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004;279(21):22267-75.
8. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437(2):169-83.
9. Calounova G, Livera G, Zhang XQ, Liu K, Gosden RG, Welsh M. The Src homology 2 domain-containing adapter protein B (SHB) regulates mouse oocyte maturation. PLoS One. 2010;5(6):e11155.
10. Kriz V, Mares J, Wentzel P, Funa NS, Calounova G, Zhang XQ, et al. Shb null allele is inherited with a transmission ratio distortion and causes reduced viability in utero. Dev Dyn. 2007;236(9):2485-92.
11. Akerblom B, Barg S, Calounova G, Mokhtari D, Jansson L, Welsh M. Impaired glucose homeostasis in Shb-/- mice. J Endocrinol. 2009;203:271-9.
12. Gustafsson K, Calounova G, Hjelm F, Kriz V, Heyman B, Gronvik KO, et al. Shb deficient mice display an augmented TH2 response in peripheral CD4+ T cells. BMC Immunol. 2011;12:3.
13. Gustafsson K, Willebrand E, Welsh M. Absence of the adaptor protein Shb potentiates the T 2 response in a mouse model of atopic dermatitis. Immunology. 2014;143:33-41.
14. Funa NS, Kriz V, Zang G, Calounova G, Akerblom B, Mares J, et al. Dysfunctional microvasculature as a consequence of shb gene inactivation causes impaired tumor growth. Cancer Res. 2009;69(5):2141-8.
15. Akerblom B, Zang G, Zhuang ZW, Calounova G, Simons M, Welsh M. Heterogeneity among RIP-Tag2 insulinomas allows vascular endothelial growth factor-A independent tumor expansion as revealed by studies in Shb mutant mice: Implications for tumor angiogenesis. Mol Oncol. 2012;6:333-46.
16. Christoffersson G, Zang G, Zhuang ZW, Vagesjo E, Simons M, Phillipson M, et al. Vascular adaptation to a dysfunctional endothelium as a consequence of Shb deficiency. Angiogenesis. 2012;15(3):469-80.
17. Zang G, Christoffersson G, Tian G, Harun-Or-Rashid M, Vagesjo E, Phillipson M, et al. Aberrant association between vascular endothelial growth factor receptor-2 and VE-cadherin in response to vascular endothelial growth factor-a in Shb-deficient lung endothelial cells. Cell Signal. 2013;25(1):85-92.
18. Crowson AN, Magro C, Miller A, Mihm Jr MC. The molecular basis of melanomagenesis and the metastatic phenotype. Semin Oncol. 2007;34(6):476-90.
19. Miller AJ, Mihm Jr MC. Melanoma. N Engl J Med. 2006;355(1):51-65.
20. Wallgard E, Larsson E, He L, Hellstrom M, Armulik A, Nisancioglu MH, et al. Identification of a core set of 58 gene transcripts with broad and specific expression in the microvasculature. Arterioscler Thromb Vasc Biol. 2008;28(8):1469-76.
21. Gustafsson K, Heffner G, Wenzel PL, Curran M, Grawe J, McKinney-Freeman SL, et al. The Src homology 2 protein Shb promotes cell cycle progression in murine hematopoietic stem cells by regulation of focal adhesion kinase activity. Exp Cell Res. 2013;319(12):1852-64.
22. Gustafsson K, Jamalpour M, Trinh C, Kharas MG, Welsh M. The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease. J Hematol Oncol. 2014;7(1):45.
23. Stackpole CW. Distinct lung-colonizing and lung-metastasizing cell populations in B16 mouse melanoma. Nature. 1981;289(5800):798-800.
24. Gaengel K, Genove G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29(5):630-8.
25. Goritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisen J. A pericyte origin of spinal cord scar tissue. Science. 2011;333(6039):238-42.
26. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-63.
27. Straume O, Salvesen HB, Akslen LA. Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol. 1999;15(3):595-9.
28. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene. 2003;22(20):3172-9.
29. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol. 2007;34(6):555-65.
30. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008;49(2):522-7.
31. Nisancioglu MH, Betsholtz C, Genove G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 2010;70(12):5109-15.
32. Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res. 2009;22(2):175-86.
33. Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ. Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol. 2012;132(2):274-83.
34. Vianello F, Papeta N, Chen T, Kraft P, White N, Hart WK, et al. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol. 2006;176(5):2902-14.
35. Girard E, Strathdee C, Trueblood E, Queva C. Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model. Br J Cancer. 2012;107(9):1498-505.
36. Hoejberg L, Bastholt L, Schmidt H. Interleukin-6 and melanoma. Melanoma Res. 2012;22(5):327-33.
37. Gao K, Li X, Zhang L, Bai L, Dong W, Shi G, et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 2013;335(2):463-71.
38. Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP, et al. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther. 2006;5(10):2592-9.
39. Nakasone Y, Fujimoto M, Matsushita T, Hamaguchi Y, Huu DL, Yanaba M, et al. Host-derived MCP-1 and MIP-1alpha regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. Am J Pathol. 2012;180(1):365-74.
40. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. Immunol Res: Cancer; 2014.
41. Cao R, Xue Y, Hedlund EM, Zhong Z, Tritsaris K, Tondelli B, et al. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci U S A. 2010;107(2):856-61.
42. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci. 2002;115(Pt 12):2559-67.
43. Taylor AP, Rodriguez M, Adams K, Goldenberg DM, Blumenthal RD. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer. 2003;105(2):158-64.
44. Deissler HL, Deissler H, Lang GK, Lang GE. VEGF but not PlGF disturbs the barrier of retinal endothelial cells. Exp Eye Res. 2013;115:162-71.
45. Gaal EI, Tammela T, Anisimov A, Marbacher S, Honkanen P, Zarkada G, et al. Comparison of vascular growth factors in the murine brain reveals placenta growth factor as prime candidate for CNS revascularization. Blood. 2013;122(5):658-65.
46. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res. 2009;69(1):369-78.
47. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266-76.
48. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J. 2012;31(7):1692-703.
49. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299-309.